{"id":7301,"date":"2020-06-03T13:06:03","date_gmt":"2020-06-03T20:06:03","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7301"},"modified":"2021-03-24T13:06:46","modified_gmt":"2021-03-24T20:06:46","slug":"a-randomized-trial-of-hydroxychloroquine-as-postexposure-prophylaxis-for-covid-19","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/03\/a-randomized-trial-of-hydroxychloroquine-as-postexposure-prophylaxis-for-covid-19\/","title":{"rendered":"A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">A<\/span><span data-contrast=\"auto\">\u00a0place<\/span><span data-contrast=\"auto\">bo-controlled randomized<\/span><span data-contrast=\"auto\">\u00a0trial<\/span><span data-contrast=\"auto\">\u00a0of<\/span><span data-contrast=\"auto\">\u00a0hydroxychloroquine as post<\/span><span data-contrast=\"auto\">&#8211;<\/span><span data-contrast=\"auto\">exposure prophylaxis\u00a0<\/span><span data-contrast=\"auto\">(PEP)\u00a0<\/span><span data-contrast=\"auto\">for SARS-CoV-2<\/span><span data-contrast=\"auto\">\u00a0found no evidence of efficacy<\/span><span data-contrast=\"auto\">. Among 821 asymptomatic participants, 88% reported a high-risk exposure to a confirmed\u00a0<\/span><span data-contrast=\"auto\">C<\/span><span data-contrast=\"auto\">OVID<\/span><span data-contrast=\"auto\">-19 case<\/span><span data-contrast=\"auto\">. There was no difference in SARS-CoV-2 acquisition between participants receiving hydroxychloroquine (<\/span><span data-contrast=\"auto\">12<\/span><span data-contrast=\"auto\">%) and those receiving placebo (<\/span><span data-contrast=\"auto\">14<\/span><span data-contrast=\"auto\">%)<\/span><span data-contrast=\"auto\">.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"34\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">No serious adverse reactions were reported, although side effects were more common with hydroxychloroquine than with placebo (40% vs. 17%).<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Boulware et al. (June 3, 2020)<\/span><\/i><i><span data-contrast=\"none\">\u00a0A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.\u00a0<\/span><\/i><i><span data-contrast=\"none\">The New England Journal of Medicine.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2016638\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1056\/NEJMoa2016638<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A\u00a0placebo-controlled randomized\u00a0trial\u00a0of\u00a0hydroxychloroquine as post&#8211;exposure prophylaxis\u00a0(PEP)\u00a0for SARS-CoV-2\u00a0found no evidence of efficacy. Among 821 asymptomatic participants, 88% reported a high-risk exposure to a confirmed\u00a0COVID-19 case. There was no difference in SARS-CoV-2 acquisition between participants receiving hydroxychloroquine (12%) and those receiving placebo (14%).\u00a0\u00a0 No serious adverse reactions were reported, although side effects were more common with hydroxychloroquine than&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/06\/03\/a-randomized-trial-of-hydroxychloroquine-as-postexposure-prophylaxis-for-covid-19\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[19],"class_list":["post-7301","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7301"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7301\/revisions"}],"predecessor-version":[{"id":7302,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7301\/revisions\/7302"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7301"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}